Cytokine-Enhanced Vaccine and Interferon-β plus Suicide Gene Therapy as Surgery Adjuvant Treatments for Spontaneous Canine Melanoma

Human Gene Therapy

Volumn 26, Issue 6, 2015, Pages 367-376

  Finocchiaro, Liliana M E ^a   Fondello, Chiara ^a   Gil Cardeza, María L ^a   Rossi, Úrsula A ^a   Villaverde, Marcela S ^a   Riveros, María D ^a   Glikin, Gerardo C ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; BETA INTERFERON; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LIPOPLEX; THYMIDINE KINASE; CANCER VACCINE; CYTOKINE; IMMUNOLOGICAL ADJUVANT;

ADOLESCENT; ADULT; ANIMAL CELL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHILD; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXICITY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; DRUG EFFECT; FEMALE; FOLLOW UP; GENETIC IMMUNIZATION; HERPES SIMPLEX VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNOGENETICS; LOCAL THERAPY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS FREE SURVIVAL; MULTICELLULAR SPHEROID; MULTIMODALITY CANCER THERAPY; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SCHOOL CHILD; SUICIDE GENE; SUICIDE GENE THERAPY; SYSTEMIC DISEASE; SYSTEMIC THERAPY; TIME TO TREATMENT; ANIMAL; CLINICAL TRIAL; DOG; DOG DISEASES; GENE THERAPY; GENETICS; METABOLISM; MORTALITY; MULTICENTER STUDY; PROCEDURES; SUICIDE TRANSGENE; TREATMENT OUTCOME; VETERINARY;

SIMPLEXVIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; COMBINED MODALITY THERAPY; CYTOKINES; DOG DISEASES; DOGS; FEMALE; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; INTERFERON-BETA; MALE; MELANOMA; TREATMENT OUTCOME;

EID: 84932627966     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2014.130     Document Type: Article

References (24)

1. Simpson RM, Bastian BC, Michael HT, et al. Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma. Pigment Cell Melanoma Res 2014;27:37-47.
2. Hansen K, Khanna C. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer 2004;40:858-880.
3. Ramos-Vara JA, Beissenherz ME, Miller MA, et al. Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases. Vet Pathol 2000;37:597-608.
4. Smith SH, Goldschmidt MH, McManus PM. A comparative review of melanocytic neoplasms. Vet Pathol 2002;39:651-678.
5. Modiano JF, Breen M, Lana SL, et al. Naturally occurring translational models for development of cancer gene therapy. Gene Ther Mol Biol 2006;10:31-40.
6. Glikin GC, Finocchiaro LME. Clinical trials of immunogene therapy for spontaneous tumors in companion animals. ScientificWorldJournal 2014;2014:718520.
7. Grosenbaugh DA, Leard AT, Bergman PJ, et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res 2011;72:1631-1638.
8. Finocchiaro LME, Glikin GC. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up. Cancer Gene Ther 2012;19:852-861.
9. Finocchiaro LME, Villaverde MS, Gil Cardeza ML, et al. Cytokine-enhanced vaccine and interferon-β plus suicide gene as combined therapy for spontaneous canine sarcomas. Res Vet Sci 2011;91:230-234.
10. Finocchiaro LME, Spector A, Rossi UA, et al. The potential of suicide plus immune gene therapy for treating osteosarcoma: the experience on canine veterinary patients. In: Sarcoma: Symptoms, Causes and Treatments. EJ Butler, ed. (Nova Science Publishers, New York, NY). 2012; pp.107-122.
11. Finocchiaro LME, Fiszman GL, Karara AL, et al. Suicide gene and cytokines combined non viral gene therapy for spontaneous canine melanoma. Cancer Gene Ther 2008;15:165-172.
12. Gil-Cardeza ML, Villaverde MS, Fiszman GL, et al. Suicide gene therapy on spontaneous canine melanoma: correlations between in vivo tumors and their derived multicell spheroids in vitro. Gene Ther 2010;17:26-36.
13. Finocchiaro LME, Glikin GC. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma. Gene Ther 2008;15:267-276.
14. Villaverde MS, Gil-Cardeza ML, Glikin GC, et al. Interferon-β lipofection I. Increased efficacy of chemotherapeutic drugs on human tumor cells derived monolayers and spheroids. Cancer Gene Ther 2012;19:508-516.
15. Yoshida J, Mizuno M, Wakabayashi T. Interferon-beta gene therapy for cancer: basic research to clinical application. Cancer Sci 2004;95:858-865.
16. Streck CJ, Dickson PV, Ng CY, et al. Antitumor efficacy of AAV-mediated systemic delivery of interferon-beta. Cancer Gene Ther 2006;13:99-106.
17. Villaverde MS, Combe K, Duchene AG, et al. Suicide plus immune gene therapy prevents post-surgical local relapse and increases overall survival in an aggressive mouse melanoma setting. Int Immunopharmacol 2014;22:167-175.
18. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869.
19. Fuertes MB, Woo SR, Burnett B, et al. Type I interferon response and innate immune sensing of cancer. Trends Immunol 2013;34:67-73.
20. Marabelle A, Kohrt H, Caux C, et al. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014;20:1747-1756.
21. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 2000;60:3989-3999.
22. Roman M, Martin-Orozco E, Goodman JS, et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997;3:849-854.
23. Li S, Wilkinson M, Xia X, et al. Induction of IFN-regulated factors and antitumoral surveillance by transfected placebo plasmid DNA. Mol Ther 2005;11:112-119.
24. Veterinary Co-operative Oncology Group. Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:195-213.